-
Clinical observation of the effects of idebenone on Parkinsons disease
- ZHANG Xiaotao, HE Tianqi, ZHU Meijia, TANG Jiyou, ZHAO Zhangning, MAO Fei, FANG Yuqing, LIU Xiaomin, MA Gaoting, ZHANG Xiaoyu, ZHANG Xiao, WANG Min, LI Xiuhua
-
Journal of Shandong University (Health Sciences). 2019, 57(4):
34-41.
doi:10.6040/j.issn.1671-7554.0.2018.1301
-
Abstract
(
856 )
PDF (1024KB)
(
66
)
Save
-
References |
Related Articles |
Metrics
Objective To investigate the effects of idebenone(IDE)on the motor and non-motor symptoms in patients with Parkinsons disease(PD)and to explore its neuroprotective effect. Methods A total of 200 PD patients were randomly divided into the IDE group(IDE+routine treatment)and routine group(routine treatment). The scores of Unified Parkinsons Disease Rating-III(on-stimulation), UPDRS-III(off-stimulation), Montreal Cognitive Assessment(MOCA), Pittsburgh Sleep Quality Index(PSQI), and Non-Motor Symptoms Scale for Parkinsons Disease(NMSS)were monitored before treatment and 3, 6, 9, 12, 15 and 18 months after treatment. Furthermore, changes of plasma superoxide dismutase(SOD)and uric acid were detected before treatment and 6, 12 and 18 months after treatment. Results (1) In month 3, 6, 9, 12, 15 and 18 after treatment, the score of UPDRS-III(on-stimulation)in the IDE group versus that in the routine group was 16.64±6.08 vs 16.79±6.44, 14.69±5.33 vs 15.64±6.16, 12.81±4.73 vs 14.58±5.86, 11.04±3.95 vs 13.54±5.56, 9.664±3.43 vs 12.41±5.11 and 8.471±3.09 vs 11.16±4.65, respectively. In month 3 and 6, there was no difference between the two groups (P>0.05). In month 9, 12, 15 and 18, the score was significantly lower in the IDE group than in the routine group(P<0.05). (2) In month 3, 6, 9, 12, 15 and 18 after treatment, the score of UPDRS-III(off-stimulation)in the IDE group versus that in the routine group was 23.09±8.63 vs 19.85±7.20, 21.10±7.13 vs 19.63±6.85, 19.30±6.24 vs 19.13±6.57, 17.39±5.37 vs 18.32±6.28, 15.65±4.78 vs 17.35±5.97 and 14.05±4.25 vs 16.10±5.64, respectively. In month 3, 6, 9 and 12, there was no difference between the two groups(P>0.05). In month 15 and 18, the score was significantly lower in the IDE group than in the routine group(P<0.05). (3) In month 3, 6, 9, 12, 15 and 18 after treatment, the MOCA score in the IDE group versus that in the routine group was 21.68±4.59 vs 22.13±4.64, 23.02±3.60 vs 22.69±4.23, 24.39±2.66 vs 23.40±3.69, 25.30±2.12 vs 24.20±3.18, 25.94±1.81 vs 25.17±2.66 and 24.72±2.23 vs 24.27±2.94, respectively. In month 3, 6 and 18, there was no significant difference between the two groups(P>0.05). In month 9, 12 and 15, the score was significantly higher in the IDE group than in the routine group(P<0.05). (4) In month 3, 6, 9, 12, 15 and 18 after treatment, the PSQI score in the IDE group versus that in the routine group was 6.36±4.26 vs 6.12±4.19, 5.33±3.84 vs 5.25±3.85, 4.59±3.45 vs 4.50±3.50, 3.32±2.92 vs 3.51±3.27, 2.71±2.38 vs 3.26±3.03 and 2.20±2.02 vs 3.04±2.84, respectively. In month 3, 6, 9, 12 and 15, there was no difference between the two groups(P>0.05). In month 18, the score was significantly lower in the IDE group than in the routine group(P<0.05). (5) In month 3, 6, 9, 12, 15 and 18 after treatment, the NMSS score in the IDE group versus that in the routine group was 54.6±31.87 vs 54.56±33.26, 52.01±30.11 vs 52.42±32.02, 46.84±30.76 vs 50.38±30.65, 41.20±29.60 vs 46.97±28.05, 38.77±26.67 vs 43.18±24.65, 36.63±25.39 vs 41.03±23.48, respectively. There was no significant difference between the two groups(P>0.05). (6) In month 6, 12 and 18 after treatment, the level of uric acid in the IDE group versus the routine group was(253.81±111.86)vs (217.82±103.24)μmol/L,(272.56±111.04)vs (198.90±102.36)μmol/L, and(280.12±111.09)μmol/L vs(191.97±101.81)μmol/L, respectively. The level of uric acid was significantly higher in the IDE group than in the routine group(P<0.05). (7) In month 6, 12 and 18, the SOD level in the IDE group versus that in the routine group was(154.45±39.96)vs (126.47±41.30)U/mL,(162.45±42.08)vs (119.36±39.71)U/mL, and(172.90±41.78)vs (112.17±37.17)U/mL, respectively. The SOD level was significantly higher in the IDE group than in the routine group(P<0.05). Conclusion IDE can improve the motor and non-motor symptoms in PD patients and slow down the progression of the disease. It has a certain neuroprotective effect on PD.